Join
Live feed
·
PRReleasevia Quantisnow
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

ByQuantisnow·Wall Street's wire, on your screen.
ERNA· Ernexa Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ERNA (Ernexa Therapeutics Inc.) and more on Quantisnow.